Book a Call
MDside
Book a Call

GLP-1s and the brain: Parkinson’s, Alzheimer’s and mood

  • MDside
  • October 9, 2026

Key points

  • In early Parkinson’s disease, lixisenatide was associated with less motor progression at 12 months (3.08-point difference on MDS-UPDRS III) in a phase 2 trial published in NEJM [2].
  • The phase 3 exenatide trial in Parkinson’s (194 patients, 96 weeks) showed no disease-modifying effect, although it was safe and well tolerated [3].
  • EVOKE and EVOKE+ (3,808 patients with early Alzheimer’s) found that oral semaglutide did not slow clinical progression at 104 weeks [5].
  • In type 2 diabetes, cardiovascular trials and cohorts associate GLP-1s with less dementia (OR 0.55 in a meta-analysis of randomized trials) [6][7].
  • The EMA (2024) concluded that the evidence does not support a causal link with suicidal ideation or behavior, and FDA (2026) did not identify an increased risk [10][13].

US status (October 2026): Semaglutide is FDA-approved as Ozempic, Rybelsus and Wegovy, with no approved neurological indication; a 503A pharmacy may compound it only for a named patient inside FDA’s copy limits. See semaglutide status.

The hypothesis started in animal models

Exenatide and lixisenatide showed neuroprotective effects in animal models of Parkinson’s disease, and liraglutide in Alzheimer’s models [1][2][4]. Then came data from patients with type 2 diabetes, in whom GLP-1 users were associated with fewer dementia diagnoses [6][8]. On that basis, randomized trials were launched in neurodegenerative diseases, which is unusual for a metabolic drug.

Parkinson’s: three trials, two directions

  • Exenatide, Lancet 2017 (62 patients with moderate Parkinson’s, 48 weeks plus 12 weeks of washout): at 60 weeks, the off-medication MDS-UPDRS III improved by 1.0 point with exenatide and worsened by 2.1 with placebo; adjusted difference -3.5 points (p = 0.0318). The authors noted that an effect on the disease could not be distinguished from a long-lasting symptomatic effect [1].
  • Lixisenatide, NEJM 2024 (LIXIPARK) (156 patients diagnosed less than 3 years earlier, 12 months): MDS-UPDRS III changed by -0.04 with lixisenatide versus +3.04 with placebo; difference 3.08 (95% CI 0.86 to 5.30; P = 0.007). Other secondary end points did not differ substantially. Nausea occurred in 46% and vomiting in 13% [2].
  • Exenatide, Lancet 2025 (phase 3) (194 patients, 96 weeks, six UK hospitals): off-medication MDS-UPDRS III worsened by 5.7 points with exenatide and 4.5 with placebo; coefficient 0.92 (95% CI -1.56 to 3.39; p = 0.47). The authors concluded there is no evidence to support exenatide as a disease-modifying treatment for Parkinson’s [3]. In June 2026, The Lancet published an expression of concern about this paper [14].

The largest and longest trial was the negative one. Its authors propose studying agents with better target engagement, or specific patient subgroups, to establish whether the class has any role in Parkinson’s [3]. Lixisenatide remains an isolated positive signal, awaiting the “longer and larger trials” its authors call for [2].

Alzheimer’s: ELAD and EVOKE were both negative on their main outcomes

ELAD (phase 2b, 204 patients without diabetes with mild to moderate Alzheimer’s, 52 weeks of liraglutide) missed its primary outcome: cerebral glucose metabolism on PET did not differ between groups. A secondary executive scale (ADAS-Exec) favored liraglutide (0.15; 95% CI 0.03 to 0.28; unadjusted p = 0.01), with no difference in CDR-SB [4].

EVOKE and EVOKE+ were the definitive test: two phase 3 trials at 566 sites in 40 countries, 3,808 patients aged 55 to 85 with amyloid-confirmed Alzheimer’s at the mild cognitive impairment or mild dementia stage, given oral semaglutide up to 14 mg daily or placebo. At 104 weeks, CDR-SB worsened equally in both arms: difference -0.08 (p = 0.57) in EVOKE and 0.10 (p = 0.46) in EVOKE+. Both trials were discontinued due to negative clinical outcome. Safety was as expected for semaglutide [5].

The observational signal is still there

  • 0.47: HR for dementia with GLP-1s versus placebo in 15,820 patients from three cardiovascular trials [6]
  • 0.55: OR for dementia with GLP-1s in a meta-analysis of randomized trials (10 GLP-1 trials) [7]
  • 0.33: HR for first Alzheimer’s diagnosis with semaglutide versus insulin [8]

In type 2 diabetes the data are consistent. In the pooled analysis of three double-blind cardiovascular trials, dementia was less frequent with GLP-1s than with placebo (HR 0.47; 95% CI 0.25 to 0.86), and in a Danish registry of 120,054 patients each additional year of exposure was associated with an HR of 0.89 [6]. A meta-analysis of randomized trials in JAMA Neurology found a reduction in dementia with GLP-1s (OR 0.55) that was not seen with SGLT2 inhibitors [7].

Target-trial emulations point the same way. Using health records of 1,094,761 US patients with type 2 diabetes, semaglutide was associated with fewer first Alzheimer’s diagnoses, with an HR of 0.33 versus insulin and 0.59 versus other GLP-1s [8]. In 2026, among 1,320 patients with type 2 diabetes and mild cognitive impairment, starting a GLP-1 rather than a DPP-4 inhibitor was associated with less dementia (HR 0.74) over up to 5 years, with a number needed to treat of 21 [9].

Cohorts and trials studied different people

The positive signal comes from people with type 2 diabetes, without dementia, treated for years. EVOKE studied a different population: already symptomatic, amyloid-confirmed Alzheimer’s, and 86% without type 2 diabetes [9]. The authors of the 2026 study note that it was unclear whether GLP-1s influence progression to dementia in people with type 2 diabetes and mild cognitive impairment, and they describe their own work as hypothesis-generating [9]. The authors of the 2024 emulation also call for clinical trials to confirm the finding [8].

The honest limits. No GLP-1 agonist has an approved indication for Alzheimer’s or Parkinson’s disease. The two largest and longest trials were negative [3][5]. What remains is a prevention signal in type 2 diabetes, supported by cardiovascular trials and cohorts [6][7], that has not yet been tested in a trial designed for that purpose.

The suicidality alarm was not confirmed

In July 2023 the EMA opened a review after reports of suicidal thoughts with liraglutide and semaglutide. In April 2024 its pharmacovigilance committee (PRAC) concluded that the available evidence does not support a causal association between GLP-1s (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide) and suicidal or self-injurious thoughts and actions [10].

  • In a cohort of 240,618 patients with overweight or obesity, semaglutide was associated with a lower risk of incident (HR 0.27) and recurrent (HR 0.44) suicidal ideation versus other anti-obesity drugs, with findings replicated in type 2 diabetes [11].
  • In Swedish and Danish registers, with 124,517 GLP-1 users versus 174,036 SGLT2 users, the HR for suicide death was 1.25 (95% CI 0.83 to 1.88), not significant. For suicide or self-harm it was 0.83, and for incident depression or anxiety, 1.01 [12].
  • In January 2026 FDA analyzed 91 placebo-controlled trials with 107,910 patients, found no increased risk and asked for the warning to be removed from the Saxenda, Wegovy and Zepbound labels [13].

The effect on alcohol use, the other major central nervous system signal, has been tested in randomized trials and is covered in Semaglutide and alcohol.

What to tell the patient who asks

On current data, you can say four things. In people with type 2 diabetes, GLP-1s were associated with less dementia in cardiovascular trials and large cohorts [6][7][8]. They have not been shown to slow Alzheimer’s disease once diagnosed [5]. In Parkinson’s there is one positive phase 2 trial and one negative phase 3 [2][3]. Regulators found no evidence of an increased suicidality risk [10][13]. The safety profile is reassuring. Neurological efficacy is an open question.

Prescribe for the approved indication, document that the brain data are unproven, and do not market a GLP-1 program on dementia prevention. For how MDside structures approved GLP-1 care, see weight management, and for sourcing rules, compounded GLP-1s after the shortage.

References

  1. Athauda D, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675. PMID 28781108. Link
  2. Meissner WG, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med. 2024;390(13):1176-1185. PMID 38598572. Link
  3. Vijiaratnam N, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10479):627-636. PMID 39919773. Link
  4. Edison P, et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nat Med. 2026;32(1):353-361. PMID 41326666. Link
  5. Cummings JL, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer’s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. PMID 41865758. Link
  6. Nørgaard CH, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement (N Y). 2022;8(1):e12268. PMID 35229024. Link
  7. Seminer A, et al. Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. JAMA Neurol. 2025;82(5):450-460. PMID 40193122. Link
  8. Wang W, et al. Associations of semaglutide with first-time diagnosis of Alzheimer’s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661-8672. PMID 39445596. Link
  9. Schechter M, et al. Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study. Alzheimers Dement (N Y). 2026;12(3):e70315. PMID 42769274. Link
  10. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024. 12 April 2024. Link
  11. Wang W, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176. PMID 38182782. Link
  12. Ueda P, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184(11):1301-1312. PMID 39226030. Link
  13. U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. 13 January 2026. Link
  14. The Editors of The Lancet. Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2026;407(10548):2588. PMID 42330995. Link

This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.

Share this article with a friend

Medical direction. Victor D. Cruz, MD, Systems Medical Director, licensed in Florida (ME117105) and New York, directs structure, corporate practice of medicine, delegation and good faith exams. This states who carries clinical responsibility for this subject area. It is not a page-level review: pages that have been reviewed name the reviewer and show the date. How this site is written and checked.